After 280E: Why Smart Cannabis Operators Are Turning Their Tax Savings Into Financial Assets

For more than a decade, IRS Section 280E was the tax code’s most punishing anomaly—a Cold War-era provision designed to deny deductions to drug traffickers that ended up strangling legal cannabis businesses. Dispensaries, cultivators, and processors operating entirely within state law paid effective federal income tax rates that could exceed 70 percent, because 280E barred them from deducting ordinary business expenses: payroll, rent, marketing, utilities. Everything except the direct cost of goods sold.

The provision didn’t just hurt profits. It warped the entire financial architecture of the cannabis industry, forcing operators to structure their businesses around a tax burden that no comparable consumer goods company would recognize.

Now, with federal cannabis rescheduling advancing and 280E’s grip weakening, the question isn’t just “how much money do we get back?” It’s something more strategic: what do operators do with the capital they’ve been hemorrhaging for years—and how do they build something that won’t collapse the next time Washington changes the rules?

What 280E Actually Did to the Industry

To understand the post-280E moment, it helps to understand what the provision actually meant at the operator level.

Section 280E of the Internal Revenue Code states that no deduction or credit shall be allowed for expenses incurred in a trade or business that consists of trafficking in Schedule I or II controlled substances. Cannabis, as a Schedule I drug under the Controlled Substances Act, has been squarely in that category since the first state-legal dispensaries opened.

The practical effect was catastrophic for cash flow. A multistate operator running $50 million in annual revenue might clear a 20 percent operating margin before taxes—a respectable number in any industry. Under 280E, that same company could face a federal tax bill calculated on gross profit rather than net income, obliterating what looked like profitability on paper. Industry analysts have estimated that 280E cost cannabis businesses collectively billions of dollars in excess taxation over the past decade-plus.

Worse, because cannabis businesses couldn’t access standard business banking—another consequence of federal illegality—they couldn’t borrow cheaply to smooth those tax hits. They paid the bill in cash, often literally.

Rescheduling Changed the Math

The DEA’s ongoing rescheduling process—moving cannabis from Schedule I to Schedule III—doesn’t legalize cannabis under federal law. What it does do is remove the Schedule I and II designation that makes 280E apply in the first place.

That’s significant. A Schedule III classification means cannabis businesses could, for the first time, deduct ordinary business expenses on their federal returns. The effective tax rate for a well-run operator could drop from punishing to something approaching normal—freeing up capital that has essentially been locked inside the federal government’s coffers for years.

But here’s where policy intersects with business strategy: operators who spent the 280E era barely surviving have to decide, fast, what to do with that margin. And the answers being proposed are more sophisticated than just pocketing the difference.

Captive Insurance: Converting Risk Into an Asset

One strategy gaining serious traction in the post-280E conversation is the captive insurance structure. The concept is not new in corporate America—large companies from Fortune 500 manufacturers to hospital chains have used captives for decades—but it’s largely untested in cannabis because the industry has been too financially constrained to set one up properly.

The basic mechanics: an operator creates a wholly-owned insurance subsidiary—the captive—that underwrites risks specific to the parent business. Rather than paying premiums to a third-party insurer (which cannabis companies have always struggled to find on reasonable terms), the operator pays premiums to its own captive. Those premiums are a deductible business expense for the parent. The captive accumulates reserves, invests them, and pays claims when they arise.

The result, when structured correctly, is that capital the operator would have spent on insurance premiums—or worse, held as naked cash reserves against uninsurable risks—becomes owned capital within the enterprise. It generates investment returns. It builds surplus. Risk goes from being a pure cost center to being a financial asset on the balance sheet.

For cannabis operators, this is particularly powerful because the industry has historically faced a brutal insurance market. Standard commercial carriers either won’t write cannabis policies or charge stratospheric premiums for coverage that barely covers what operators actually need. A captive sidesteps that market entirely, allowing operators to design coverage around the actual risk profile of their business: crop loss, product liability, regulatory action, employee practices, business interruption.

The post-280E context supercharges this. With effective tax rates dropping and real cash flow materializing for the first time, operators have the capital to actually fund a captive’s initial reserve requirements—typically several hundred thousand to low millions depending on structure and domicile. That was simply not available to most cannabis businesses under 280E’s punishing regime.

Banking Access Remains the Constraint

The captive insurance story doesn’t exist in isolation. It sits alongside a broader structural shift in cannabis finance that has been accelerating as federal policy moves—however slowly—toward normalization.

The cannabis lending market has seen notable movement recently, with institutional capital beginning to view the sector differently. A $60 million institutional-backed cannabis credit facility launched by FundCanna signals that some financial players are no longer waiting for full federal legalization before entering the space. For years, cannabis operators paid rates on debt that would make a subprime mortgage look generous. Institutional credit facilities at scale suggest that calculus is changing.

The through-line from 280E reform to captive insurance to institutional lending is the same: cannabis businesses are beginning to access the standard toolkit of corporate financial management that every other industry takes for granted. Risk management. Tax efficiency. Reasonably priced debt.

What Washington Still Needs to Do

None of this happens automatically. DEA rescheduling is proceeding, but it remains incomplete—the comment period generated tens of thousands of submissions, and the administrative process has no hard deadline for resolution. Congressional action on cannabis banking, through vehicles like the SAFER Banking Act or successor legislation, remains stalled despite periodic momentum.

The financial strategies being developed by cannabis operators right now are built on an assumption that rescheduling will complete and that 280E will cease to apply. That assumption is reasonable but not guaranteed. A change in administration, a legal challenge to the rescheduling rule, or a hostile Congress could complicate the picture.

What operators are doing—building financial infrastructure that treats the business like a normal business—is exactly the right instinct. The question is whether Washington will hold up its end of the bargain.

For now, the post-280E moment is arriving, piece by piece. Operators who spent a decade paying an illegal penalty for being legal businesses are finally getting to ask a better question: not how do we survive the tax bill, but how do we build something that lasts.

Ethan Vale covers federal cannabis policy, the DEA and DOJ, Congress, and cannabis banking for CannabisInquirer.com.